TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31176622
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa)
Study: 31176622
Drug: Luteinising hormone-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinising hormone-releasing hormone agonist (LHRHa) alone
Study: 27258183
Drug: Parkinson disease
Normalized name: Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parkinson disease patients walking in medication-off condition
Study: 19065889
Drug: Compound Tongfu
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Tongfu Granule (CTG)
Study: 15839187
Drug: Glipizide monotherapy
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide monotherapy
Study: 8869440
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS), 2 puffs (2 mg puff-1) administered three times a day via a spacer device and face mask
Study: 6702646
Drug: Nifedipine (N),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (N), 20 mg, 3 times daily
Study: 31205087
Drug: R‐spondin1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐spondin1 treatment
Study: 25136077
Drug: Delayed programming
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed programming (60-second delay before therapy ≥170 beats per minute)
Study: 19481335
Drug: Daily tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tamoxifen 20mg continuously (daily group)
Study: 19481335
Drug: Weekly tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Study: 19481335
Drug: Daily tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tamoxifen 20mg continuously (daily group) and Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Study: 17353504
Drug: Exenatide LAR
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide LAR 0.8 mg
Study: 17353504
Drug: Exenatide LAR
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide LAR 2.0 mg
Study: 3619195
Drug: terfenadine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 180 mg
Study: 2746641
Drug: Single 50‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 50‐mg dose of riboflavin
Study: 2746641
Drug: More frequent
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More frequent dosage of riboflavin
Study: 4349414
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from drugs
Study: 25947394
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Lipo‐PGE1 (Group A)
Study: 25947394
Drug: No Lipo‐PGE1
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Lipo‐PGE1 administration (Group B)
Study: 21602833
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg once daily plus sildenafil 25‐100 mg on demand (Group A)
Study: 21602833
Drug: Sildenafil 25‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25‐100 mg on demand (Group B)
Study: 16766780
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (6 gm, caffeine 175 mg)
Study: 16766780
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (6 gm, caffeine 125 mg)
Study: 11511821
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 120 mg daily
Study: 3088275
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of 1% lidocaine
Study: 3088275
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml of 1% lidocaine
Study: 3088275
Drug: 0 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml of lidocaine (control)
Study: 29575803
Drug: TCZ monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ monotherapy
Study: 27634376
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Study: 24118531
Drug: Isoproterenol (ISP)
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol (ISP) and adenosine triphosphate (ATP) co-administered before and after circumferential pulmonary vein isolation (CPVI)
Study: 23253702
Drug: Statins (mainly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (mainly Simvastatin 20 mg and Atorvastatin 10 mg)
Study: 20855671
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Esomeprazole, amoxicillin sodium, and clarithromycin) in patients with positive HPSA
Study: 16884979
Drug: Control (fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (fentanyl 30 microg/kg with propofol 2-8 mg/kg/h)
Study: 3320928
Drug: Cefixime, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime, 8 mg/kg daily for 10 days
Study: 3320928
Drug: Amoxicillin, 40
Normalized name: Amoxicillin, 400 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 40 mg/kg/day in three divided doses for 10 days
Study: 30853490
Drug: l-Carnitine (L-Car)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-Carnitine (L-Car)
Study: 30853490
Drug: Restricted diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted diet without L-Car
Study: 30853490
Drug: Restricted diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted diet with L-Car
Study: 16936417
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) - 2-5 microg/kg subcutaneous injection once daily for 10 days
Study: 16936417
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow transplantation (BMT) - conventional drug therapy plus BMT
Study: 10720011
Drug: Diuretic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic administration
Study: 8707483
Drug: Daily massages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily massages for one month
Study: 1514711
Drug: captopril 25-50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 25-50 mg twice daily
Study: 1514711
Drug: nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine SR 20-40 mg twice daily
Study: 30200162
Drug: Adjunct intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct intermittent pneumatic compression with pharmacologic thromboprophylaxis
Study: 24383508
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion throughout (CC)
Study: 20851295
Drug: Folate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate (5 mg) plus vitamin B12 (500 μg) supplementation
Study: 24903195
Drug: Intra-aortic Balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic Balloon Pump (IABP) therapy
Study: 24903195
Drug: No IABP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IABP therapy (Control)
Study: 15803031
Drug: Infliximab (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (maintenance therapy)
Study: 15803031
Drug: Infliximab (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (first dose)
Study: 7848022
Drug: Cholestyramine resin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine resin, 8 g/d
Study: 7848022
Drug: Cholestyramine resin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine resin, 8 g/d plus lovastatin, 5 mg/d
Study: 21560649
Drug: Alternative anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative anti-inflammatory drug based on ginger extract
Study: 15003074
Drug: Lamotrigine (100-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (100-500 mg/day)
Study: 9779760
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment with bacteriologic eradication
Study: 9779760
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment without bacteriologic eradication
Study: 9676769
Drug: Tramadol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (250 mg/day)
Study: 9676769
Drug: Tramadol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50-100 mg every 4-6 h as needed for pain)
Study: 2561281
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (S)
Study: 30952531
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (ET) including mechanical thrombectomy (MT) alone (N = 269), MT ± thrombolysis (N = 297), and thrombolysis alone (N = 682)
Study: 23926685
Drug: Control (testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (testosterone undecanoate capsules)
Study: 16952675
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg tamsulosin daily
Study: 9131726
Drug: Doxepin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin administered intravenously (125 mg) switched to oral administration (250 mg)
Study: 7641549
Drug: Laparoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic treatment (totally pre-peritoneal approach)
Study: 2567717
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal suppositories (PVS)
Study: 31907828
Drug: acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acarbose 50 mg for 1 week
Study: 31907828
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg for 1 week
Study: 31907828
Drug: verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 120 mg for 1 week
Study: 31907828
Drug: liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.2 mg for 3 weeks
Study: 31907828
Drug: pasireotide 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: pasireotide 300 μg as a single dose
Study: 31144430
Drug: baseline period
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline period without treatment
Study: 28608641
Drug: Intensive immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive immunosuppressive regimen (including ATG, steroid therapy, high CNI doses)
Study: 21526229
Drug: Daily micronutrient-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily micronutrient-rich nutritional supplement
Study: 21526229
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (nutritional supplement and physical activity)
Study: 18843004
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein intake containing 99 mg isoflavones daily
Study: 8759268
Drug: Sulphapyridine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphapyridine 500 mg twice daily
Study: 28838010
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (O2) at 10 L/min via facemask
Study: 27412188
Drug: Control (discontinue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (discontinue all hypertensive medications)
Study: 18923311
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy and exercise (MTE)
Study: 12519101
Drug: Quetiapine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine therapy
Study: 7769807
Drug: Enalaprilat 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 0.25 mg/h
Study: 7769807
Drug: Enalaprilat 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 0.5 mg/h
Study: 2022712
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10-amino acid mixture
Study: 7066166
Drug: Spironolactone 200
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 200 mg
Study: 26281178
Drug: Livodexa (Sun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livodexa (Sun Pharmaceutical Industries Ltd, India)
Study: 11152850
Drug: High-dose simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose simvastatin
Study: 9890203
Drug: Isoproterenol, acetylcholine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol, acetylcholine, and nitroglycerin (dosage not specified)
Study: 7905097
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow infusion after a 10 day course of antithymocyte globulin, 5 days post-transplantation.
Study: 7905097
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what treatment they received).
Study: 7905097
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow infusion group.
Study: 23917673
Drug: Methadone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (5 mg bid)
Study: 19035101
Drug: TACE +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE + HITT therapy
Study: 19035101
Drug: TACE +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE + PEI only therapy
Study: 11032201
Drug: Enhanced back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enhanced back care plus manual therapy
Study: 8330997
Drug: 1.6 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 Gy twice daily, 5 days a week, with total brain treatment to 32.0 Gy and boost doses escalating from 16.0 Gy to 42.40 Gy.
Study: 3299287
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (group A)
Study: 3299287
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (group C)
Study: 20397458
Drug: Hormone block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone block therapy and drug medication
Study: 18680246
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexrabeprazole daily
Study: 18680246
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabeprazole daily
Study: 16185308
Drug: Oxytocin treatment
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin treatment (nasal inhalation, twice daily for 13 weeks)
Study: 16185308
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (nasal inhalation, twice daily for 13 weeks)
Study: 14986908
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education program and supervised tooth brushing with fluoridated toothpaste (1100 ppm F‐) in test group (n = 258)
Study: 14986908
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 256) with no oral health education and no supervised tooth brushing
Study: 10634838
Drug: Trophic feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophic feeding (0.5‐1 ml/h) along with parenteral nutrition
Study: 6489151
Drug: High methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High methadone dose increase to 60 mg in week 4, then gradual reduction to 30 mg by week 10.
Study: 6489151
Drug: Constant 30
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant 30 mg methadone dose through treatment week 10.
Study: 6489151
Drug: High methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High methadone dose increase group (experimental)
Study: 6489151
Drug: Constant 30
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant 30 mg methadone dose group (control)
Study: 30157839
Drug: Pretreatment educational
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment educational programme followed by treatment as usual
Study: 27155741
Drug: Pictilisib (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictilisib (340 mg in part 1; 260 mg in part 2) plus fulvestrant 500 mg
Study: 27155741
Drug: Pictilisib (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictilisib (340 mg in part 1; 260 mg in part 2)
Study: 22416676
Drug: Treatment Interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Interruption (TI) arm
Study: 22416676
Drug: Treatment Continuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Continuation (TC) arm
Study: 12216432
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous 17-beta estradiol and norethindrone acetate
Study: 12216432
Drug: Transdermal cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal cyclic 17-beta estradiol and norethindrone acetate
Study: 7887385
Drug: Fosinopril 10
Normalized name: fosinopril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 10 or 20 mg/day
Study: 2532927
Drug: Terbinafine (SF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (SF 86-327, Lamisil) 250 mg daily for 6 months (finger-nail) and 12 months (toe-nail)
Study: 2532927
Drug: Terbinafine (SF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (SF 86-327, Lamisil) 250 mg daily
Study: 57520
Drug: Alice strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice strain live influenza vaccine
Study: 28931617
Drug: Normobaric hyperoxia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric hyperoxia (NBO) treatment (100% O2) in rats during middle cerebral artery occlusion.
Study: 28931617
Drug: Normobaric hyperoxia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric hyperoxia (NBO) treatment in patients with AIS receiving intravenous tPA thrombolysis.
Study: 23494931
Drug: Sildenafil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil plus testosterone gel (n=70)
Study: 23494931
Drug: Sildenafil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil plus placebo gel (n=70)
Study: 21081772
Drug: Conventional promotility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional promotility drug treatment group (DTG; metoclopramide, cisapride, erythromycin)
Study: 21081772
Drug: Conventional promotility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional promotility drugs
Study: 10818079
Drug: Fasidotril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasidotril (100 mg twice daily for 6 weeks)
Study: 8895272
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 mg
Study: 6133103
Drug: Advice on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice on cholesterol-lowering diet, smoking cessation, weight control, exercise, and treatment of hypertension.
Study: 30625070
Drug: Caplacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caplacizumab (10 mg intravenous loading bolus, followed by 10 mg daily subcutaneously)
Study: 12131314
Drug: 3.9 mg
Normalized name: menthol 3.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9 mg daily oxybutynin TDS
Study: 12131314
Drug: 2.6 mg
Normalized name: menthol 2.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 mg daily oxybutynin TDS
Study: 10102962
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (1 g sucralfate q.d.s. for 28 days, 300 mg metronidazole q.d.s. for 14 days, 250 mg clarithromycin q.d.s. for 14 days)
Study: 10102962
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg q.d.s. for 12 months)
Study: 2262904
Drug: Zolpidem (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (15, 30 and 45 mg)
Study: 2262904
Drug: Triazolam (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25, 0.5 and 0.75 mg)
Study: 30324837
Drug: 1 mg/day estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day estradiol valerate plus 4 mg/day medroxyprogesterone acetate on days 19‐30 (Group A)
Study: 30324837
Drug: 1 mg/day estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day estradiol valerate plus 100 mg/day micronized progesterone on days 19‐30 (Group B)
Study: 30324837
Drug: Cimicifuga foetida
Normalized name: Ballota foetida extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga foetida extract, 1 tablet (contains 33.3 mg extract), t.i.d. (Group C)
Study: 30022759
Drug: Pidotimod oral
Normalized name: pidotimod Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod oral liquid
Study: 30022759
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (ganciclovir for injection and symptomatic treatment)